Bulletin of Chinese Academy of Sciences (Chinese Version)


synthetic cell; synthetic bacteria; synthetic virus; synthetic phage

Document Type



In the field of medical applications, synthetic biology researchers design genetic circuits to modify human cells, or to modify synthetic organisms such as bacteria and viruses and make them interact with the human body. These artificially designed organisms are capable of perceiving disease-specific signals or artificial signals, targeting abnormal cells and foci, expressing reporter molecules or releasing therapeutic drugs, thus enabling the monitoring of human physiological conditions and the diagnosis and treatment of typical diseases such as tumors, metabolic diseases, and drug-resistant bacteria infections. This article will comprehensively describe some recent research progress.

First page


Last Page





Bulletin of Chinese Academy of Sciences


Richardson M A, Ramirez T, Russell N C, et al. Coley toxins immunotherapy:a retrospective review. Alternative Therapies in Health and Medicine, 1999, 5(3):42.

Forbes, N. S. Engineering the perfect (bacterial) cancer therapy. Nature Reviews Cancer, 2010, 10(11):785-794.

Yu B, Yang M, Shi L, et al. Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain. Scientific Reports, 2012, 2:436.

Danino T, Prindle A, Kwong G A, et al. Programmable probiotics for detection of cancer in urine. Science Translational Medicine, 2015, 7 (289):289ra84.

Din M O, Danino T, Prindle A, et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature, 2016, 536(7614):81-85.

Sheth R U, Yim S S, Wu F L, et al. Multiplex recording of cellular events over time on CRISPR biological tape. Science, 2017, 358(6369):1457-1461.

Mimee M, Nadeau P, Hayward A, et al. An ingestible bacterialelectronic system to monitor gastrointestinal health. Science, 2018, 360(6391):915-918.

Wang S, Dos-Santos A L A, Huang W, et al. Driving mosquito refractoriness to Plasmodium falciparum with engineered symbiotic bacteria. Science, 2017, 357(6358):1399-1402.

Si L, Xu H, Zhou X, et al. Generation of influenza A viruses as live but replication-incompetent virus vaccines. Science, 2016, 354(6316):1170-1173.

Li P, Ke X, Wang T, et al. Zika virus attenuation by codon pair deoptimization induces sterilizing immunity in mouse models. Journal of Virology, 2018, 92(17). pii:e00701-18.

Piotr Wnuk. Oncolytics: the dawn of a new era in cancer treatment.[2018-08-02]. https://pharmaphorum.com/views-and-analysis/oncolytics-new-era-cancer-treatment/.

吴蓉.首例超级细菌感染患者经噬菌体治疗痊愈.[2018-08-15]. http://www.sh.chinanews.com/yljk/2018-08-15/43418.shtml.

Associated Press. Second man undergoes gene editing; Therapy has no safety flags so far.[2018-02-06]. https://www.voanews.com/a/second-man-undergoes-gene-editing/4242428.html.

医麦克.潜心研究ZFN基因编辑技术20年Sangamo公司成为行业领导者.[2018-07-30]. http://med.sina.com/article_detail_103_2_49638.html.

Tom Ireland. I want to help humans genetically modify themselves.[2017-12-24]. https://www.theguardian.com/science/2017/dec/24/josiah-zayner-diy-gene-editing-therapy-crispr-interview.

Liu Y, Zeng Y, Liu L, et al. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nature Communations, 2014, 5:5393.

Roybal K T, Lim W A. Synthetic immunology:hacking immune cells to expand their therapeutic capabilities. Annual Reviews of Immunology, 2017, 35:229-253.

Nissim L, Wu M R, Pery E, et al. Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy. Cell, 2017, 171(5):1138-1150.

Xie M, Ye H, Wang H, et al. β-cell-mimetic designer cells provide closed-loop glycemic control. Science, 2016, 354(6317):1296-1301.

Ye H, Xie M, Xue S, et al. Self-adjusting synthetic gene circuit for correcting insulin resistance. Natute Biomedical Engineering, 2017, 1(1):0005.

Shao J, Xue S, Yu G, et al. Smartphone-controlled optogenetically engineered cells enable semiautomatic glucose homeostasis in diabetic mice. Science Translational Medicine, 2017, 9(387):eaal2298.

Xue S, Yin J, Shao J, et al. A synthetic-biology-inspired therapeutic strategy for targeting and treating hepatogenous diabetes. Molecular Therapy, 2017, 25(2):443-455.

Liang P, Xu Y, Zhang X, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein and Cells, 2015, 6(5):363-372.

Kang X, He W, Huang Y, et al. Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing. Journal of Assisted Reproduction and Genetics, 2016, 33(5):581-588.

Ma H, Marti-Gutierrez N, Park SW, et al. Correction of a pathogenic gene mutation in human embryos. Nature, 2017, 548(7668):413-419.

Liu Z, Cai Y, Wang Y, et al. Cloning of macaque monkeys by somatic cell nuclear transfer. Cell, 2018, 174(1):245.

Feng C, Wang X, Shi H, et al. Generation of apoe deficient dogs via combination of embryo injection of crispr/cas9 with somatic cell nuclear transfer. Journal of Genetics and Genomics, 2018, 45 (1):47-50.

Yan S, Tu Z, Liu Z, et al. A huntingtin knockin pig model recapitulates features of selective neurodegeneration in huntington's disease. Cell, 2018, 173(4):989-1002.

Ruella M, Xu J, Barrett D M, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine, 2018, 24(10):1499-1503.

US Department of Health and Human Services. Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information.[2016-06-01]. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/UCM292704.pdf.